Lisata Therapeutics Reports No Revenue and Significant Losses in Q2 2026

Lisata Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and ongoing operational challenges. The company recorded no revenue for the three and six months ended June 30, 2026, compared to $70,000 for the same periods in 2025. This drop reflects the cessation of revenue-generating activities, primarily due to the termination of a merger agreement with Kuva Labs Inc. and the subsequent impact on its operational strategy. The net loss for the second quarter was $2.9 million, a decrease from a loss of $4.7 million in the prior year, while the loss for the first half of 2026 was $7.4 million, down from $9.4 million in 2025.

Operating expenses for the second quarter totaled $4.0 million, a reduction of 19.2% from $4.9 million in the same quarter of 2025. This decrease was largely attributed to a significant reduction in research and development expenses, which fell to $584,000 from $2.3 million, primarily due to the completion of the Phase 2a Bolster trial. However, general and administrative expenses increased by 26.9% to $3.4 million, driven by higher legal and consulting fees associated with the merger discussions. For the first half of 2026, total operating expenses were $8.9 million, down from $10.8 million in the previous year.

In terms of strategic developments, Lisata announced the termination of its merger agreement with Kuva Labs on July 24, 2026, following Kuva's failure to secure financing for the transaction. The termination has led to a legal dispute, with Lisata seeking a $2 million termination fee and additional damages. The company is also exploring various strategic alternatives to enhance shareholder value, including potential mergers, acquisitions, or asset sales. However, there is substantial doubt regarding Lisata's ability to continue as a going concern, as it has limited cash reserves of approximately $10.4 million as of June 30, 2026.

Operationally, Lisata has undergone significant changes, including a workforce reduction of approximately 72% to cut costs and streamline operations. This decision is expected to incur around $1.2 million in severance costs. The company is also focusing on its investigational product, certepetide, which is designed to improve the delivery of anti-cancer therapies to solid tumors. Despite promising preclinical data, the company faces challenges in funding ongoing clinical trials and achieving regulatory approvals.

Looking ahead, Lisata's management has indicated that the company will need to secure additional funding to support its operations and clinical development programs. The ongoing legal proceedings against Kuva and the exploration of strategic alternatives are critical to the company's future. However, the uncertainty surrounding these efforts, combined with the company's history of operating losses, raises concerns about its financial stability and ability to execute its business plan effectively.